Safety, tolerability, and efficacy of metformin extended-release oral antidiabetic therapy in patients with type 2 diabetes: An observational trial in Asia

Journal of Diabetes

Volumn 4, Issue 4, 2012, Pages 395-406

  Kim, Chul Hee ^a   Han, Kyung Ah ^b   Oh, Han Jin ^c   Tan, Kevin Eng Kiat ^d   Sothiratnam, Radhakrishna ^e   Tjokroprawiro, Askandar ^f   Klein, Marcus ^g  

^a Soonchunhyang University Bucheon Hospital   (South Korea)

^b Eulji General Hospital   (South Korea)

^c Cheil General Hospital   (South Korea)

^d MOUNT ELIZABETH MEDICAL CENTRE   (Singapore)

^e Columbia Asia Hospital ^*  (Malaysia)

^f AIRLANGGA UNIVERSITY   (Indonesia)

^g Merck Pte Ltd   (Singapore)

Author keywords

Asian; Extended release; Gastrointestinal side effects; Metformin; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; METFORMIN;

ADOLESCENT; ADULT; AGED; ANTIDIABETIC ACTIVITY; ARTICLE; CHILD; DIARRHEA; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FLATULENCE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HONG KONG; HUMAN; INCIDENCE; INDONESIA; MAJOR CLINICAL STUDY; MALAYSIA; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PHILIPPINES; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SHORT COURSE THERAPY; SINGAPORE; SOUTH KOREA; TREATMENT DURATION;

ASIA; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84870313739     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/j.1753-0407.2012.00220.x     Document Type: Article

References (37)

1. Yoon KH, Lee JH, Kim JW et al. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006; 368: 1681-8.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27: 1047-53.
3. Parvez Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world: A growing challenge. N Engl J Med. 2010; 356: 213-5.
4. Chan JC, Deerochanawong C, Shera AS et al. Role of metformin in the initiation of pharmacotherapy for type 2 diabetes: An Asian-Pacific perspective. Diabetes Res Clin Pract. 2007; 75: 255-66.
5. World Health Organization. Preventing Chronic Diseases: A Vital Investment. World Health Organization, 2005. Available from: http://www.who.int/chp/chronic_disease_report/full_report.pdf (accessed 15 March 2010).
6. Asia Pacific Cohort Studies Collaboration. Prevalence of diabetes mellitus and population attributable fractions for coronary heart disease and stroke mortality in the WHO South-East Asia and Western Pacific regions. Asia Pac J Clin Nutr. 2007; 16: 187-92.
7. World Health Organization. The Impact of Chronic Disease in South-East Asia. World Health Organization, 2005. Available from: http://www.who.int/chp/chronic_disease_report/media/searo.pdf (accessed 15 March 2010).
8. World Health Organization. The Impact of Chronic Disease in the Western Pacific. World Health Organization, 2005. Available from: http://www.who.int/chp/chronic_disease_report/media/wpro.pdf, accessed 15 March 2010.
9. Fujioka K, Brazg RL, Raz I et al. Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: Results from two double-blind, placebo-controlled studies. Diabetes Obes Metab. 2005; 7: 28-39.
10. Howlett H, Davidson J. New prolonged-release metformin improves gastrointestinal tolerability. Br J Diabetes Vasc Dis. 2004; 4: 273-7.
11. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: Results of a double-blind, placebo-controlled, dose-response trial. Am J Med. 1997; 102: 491-7.
12. Timmins P, Donahue S, Meeker J, Marathe P. Steady-state pharmacokinetics of a novel extended-release metformin formulation. Clin Pharmacokinet. 2005; 44: 721-9.
13. DeFronzo RA, Goodman AM; the Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995; 333: 541-9.
14. ® XR [Metformin Hydrochloride Extended-Release Tablets] Product Information. Bristol-Myers Squibb, Princeton, NJ, 2002. Revised July 2002.
15. Haupt E, Knick B, Koschinsky T, Liebermeister H, Schneider J, Hirche H. Oral antidiabetic combination therapy with sulphonylureas and metformin. Diabetes Metab. 1991; 17: 224-31.
16. Howlett HC, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf. 1999; 20: 489-503.
17. Scarpello JHB. Optimal dosing strategies for maximising the clinical response to metformin in type 2 diabetes. Br J Diabetes Vasc Dis. 2001; 1: 28-36.
18. Paes AHP, Bakker A, Soe-Agnie S-J. Impact of dosage frequency on patient compliance. Diabetes Care. 1997; 20: 1512-7.
19. Reasner C, Göke B. Overcoming the barriers to effective glycaemic control for type 2 diabetes. Br J Diab Vasc Dis. 2002; 2: 290-5.
20. Melikian C, White TJ, Vanderplas A, Dezii CM, Chang E. Adherence to oral antidiabetic therapy in a managed care organization: A comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther. 2002; 24: 460-7.
21. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: A retrospective cohort study. Diabet Med. 2002; 19: 279-84.
22. Vidon N, Chaussade S, Noel M et al. Metformin in the digestive tract. Diabetes Res Clin Pract. 1988; 4: 223-9.
23. Donnelly LA, Morris AD, Pearson ER. Adherence in patients transferred from immediate release metformin to a sustained release formulation: A population-based study. Diabetes Obes Metab. 2009; 11: 338-42.
24. Blonde L, Joyal S, Henry D, Howlett H. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: Results of a retrospective cohort study. Curr Med Res Opin. 2004; 20: 565-72.
25. Fujioka K, Pans M, Joyal S. Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate release metformin to a once-daily extended-release formulation. Clin Ther. 2003; 25: 515-29.
26. Hebden JM, Gilchrist PJ, Blackshaw E et al. Night-time quiescence and morning activation in the human colon: Effect on transit of dispersed and large single unit formulations. Eur J Gastroenterol Hepatol. 1999; 11: 1379-85.
27. Marathe E, Turner K. Steady-state pharmacokinetics of the metformin extended release tablet versus the immediate-release metformin tablet in healthy subjects. Diabetes. 2002; 51(Suppl. 2): A474.
28. Gusler G, Gorsline J, Levy G et al. Pharmacokinetics of metformin gastric-retentive tablets in healthy volunteers. J Clin Pharmacol. 2001; 41: 655-61.
29. Gao H, Xiao W, Wang C et al. The metabolic effects of once daily extended-release metformin in patients with type 2 diabetes: A multicentre study. Int J Clin Pract. 2008; 62: 695-700.
30. ® SR) in individuals intolerant to standard metformin: Results from four UK centres. Br J Diabetes Vasc Dis. 2007; 7: 225-8.
31. Ohmura C, Tanaka Y, Mistuhashi N et al. Efficacy of low-dose metformin in Japanese patients with type 2 diabetes mellitus. Curr Ther Res. 1996; 59: 889-95.
32. Mughal MA, Jan M, Maheri WM, Memon MY, Ali M. The effect of metformin on glycemic control, serum lipids and lipoproteins in diet alone and sulfonylurea-treated type 2 diabetic patients with sub-optimal metabolic control. J Pak Med Assoc. 2000; 50: 381-6.
33. Yamanouchi T, Sakai T, Igarashi K, Ichiyanagi K, Watanabe H, Kawasaki T. Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1year in Japanese patients with newly diagnosed type 2 diabetes. Diabetes Med. 2005; 22: 980-5.
34. Chan JCN, Tomlinson B, Critchley JAJH, Cockram CS, Walden RJ. Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients. Diabetes Care. 1993; 16: 1035-8.
35. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care. 1993; 16: 621-9.
36. Ahn YB, Son HY. Efficacy of metformin monotherapy in patients with NIDDM in Korea. In: Shinn SH, Shichiri M, Kim K-W (eds). New Therapeutic Approaches in Diabetes Mellitus. Recent Advances on the Pathogenesis and Management of Diabetes Mellitus. Elsevier Science, Singapore, 1998; 49-54.
37. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-53.